Cell Therapeutics Cuts 34 Jobs
Luke Timmerman3/6/09
Cell Therapeutics has eliminated 34 jobs in connection with the sale of its lone approved drug, Zevalin. The Seattle-based biotech company (NASDAQ: CTIC), which has run dangerously low on cash, made the disclosure Friday afternoon in a filing with the Securities and Exchange Commission. The cuts represent about 28 percent of the company’s workforce, and leave it with about 88 employees.
For an updated list of layoffs at Seattle-area technology and life sciences companies, click here.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
